Prophylactic therapy for hemophilia in a developing country, Turkey

Pediatric Hematology and Oncology

Volumn 14, Issue 2, 1997, Pages 151-159

  Kavakli, Kaan ^a,b   Nişli, Güngör ^a   Aydinok, Yeşim ^a   Öztop, Senay ^a   Çetingül, Nazan ^a   Aydoǧdu, Semih ^a   Yalman, Osman ^a  

^a EGE UNIVERSITY   (Turkey)

^b EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

factor concentrates; hemophilia; prophylaxis; Third World countries; treatment on demand

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; EMOCLOT DI; KONYNE 80; NORDIATE; OCTAVI SDPLUS; PROTHROMBIN COMPLEX; UNCLASSIFIED DRUG;

ARTHROPATHY; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVELOPING COUNTRY; HEMOPHILIA; HOSPITALIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PROPHYLAXIS; TURKEY (REPUBLIC); VIRUS INFECTION;

EID: 0030939607     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019709030901     Document Type: Article

References (27)

1. Bitchell TJ. Hereditary coagulation disorders. In: Lee GR, Bithell TC, Foerster J, Athens JW, Lukens JN, eds. Wintrobe's Clinical Hematology. 9th ed. Philadelphia: Lea & Febiger; 1993:1456.
2. Nilsson IM. Hemophilia. Malmö, Sweden: Pharmacia Plasma Products; 1994:40-49.
3. Nişli G, Ōztop S, Kavakli K, et al. Hemophilia. In: Nişli G, ed. Hemophilia and Hemophilic Child (Turkish). Izmir: Ege University Press; 1994:5-20.
4. Petrini P, Lindwall N, Egberg N, Blomback H. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol. 1991;13:280-287.
5. Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta Pediatr Scand. 1976; 65:129-135.
6. Nilsson IM, Berntorp E, Löfquist T, Pettersson H. Twenty five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1994;232:25-32.
7. Gruppo RA, Bore KE, Donaldson VH. Fatal myocardial necrosis associated with prothrombin-complex-concentrate therapy in hemophilia A. N Engl J Med. 1983;309:242-243.
8. Kasper CK, Aledort L, Counts B. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemost. 1975;34:869-872.
9. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol. 1993;30(Suppl 2):3-6.
10. Pettersson H, Ahlberg A. A radiological classification of hemophilic arthropathy. Clin Orthop. 1980; 149:153-159.
11. Pettersson H, Nilsson IM, Hedner U, et al. Radiological evaluation of prophylaxis in severe haemophilia. Acta Pediatr Scand. 1981;70:565-570.
12. Mannucci PM. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates Vox Sang. 1993;64:197-203.
13. Petrini P, Lindwall N, Egberg N, Blomback H. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol. 1991;13:280-287.
14. Lusher JM. Consideration for current and future management of hemophilia and its complications. Hemophilia. 1995;1:2-10.
15. Nişli G, Kavakli K, Ōztop Ş, et al. Prophylactic therapy in hemophilia. "The Turkish experience." Turk J Haematol. 1995;14(Suppl 1):307.
16. Kavakli K. Hemofilik çocuklarda profilaksi programi ve Profilakside Ege Üniversitesi Deneyimi. In: Nişli G, ed. Hemofilik Çocuk Ve Sorunlari (Hemophilic Child and His Problems). Izmir: Ege University Press; 1995:41-49.
17. Nişli G, Kavakli K, Aydinok A, et al. Turkish experience in prophylaxis for hemophilia. Hemophilia. 1996;2(Suppl 1):21.
18. Aronstam A, Kirk PJ, McHardy, et al. Twice weekly prophylactic therapy in hemophilia A. J Clin Pathol. 1977;30:65-67.
19. Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor VTII concentrate. Arch Intern Med. 1970;25:1004-1009.
20. Schimpf K, Fiascer B, Rothmann P. Hemophilia A prophylaxis with factor VIII concentrates in a home-treatment program: a controlled study. Scand J Haematol. 1977;30(Suppl):79-80.
21. Kavakli K, Nişli G, Ōztop S, et al. Hepatitis C seroprevalence in children with thalassemia and hemophilia. Ege Tip Derg. 1995;34:191-193.
22. Arkin S. The incidence and prevalence of inhibitors after administration of various concentrates. In: Nilsson IM, Berntorp E, eds. Prophylactic Treatment of Hemophilia A and B. Current and Future Perspectives. New York: Science & Medicine; 1994:78-84.
23. De Biassi R, Rocino A, Miraglia E, et al. The impact of a very high purity factor VIII concentrate on the immune system of HIV infected hemophiliacs: a randomized, prospective, two year comparison with an intermediate purity concentrate. Blood. 1991;78:1919-1922.
24. Schramm W. Consensus recommendations for hemophilia treatment in Germany. In: Nilsson IM, ed. Hemophilia. Malmō, Sweden: Pharmacia Plasma Products; 1994:13-14.
25. Aledort L. Experience with prophylactic treatment in the USA. Clinical benefits: a multi-center view. In: Prophylaxis in Hemophilia. Oxford: Royal Society of Medicine Services. Alden Press; 1991:26-31. Round Table Series No. 25.
26. Aledort L. Prophylaxis for hemophilia - can we afford it? Abstract Book, Global Investigators Meeting, February 29, 1996, Bermuda.
27. Martinowitz U, Schulman S, Gital S, et al. Adjusted dose continuous infusion of factor VIII in patients with hemophilia A. Br J Haematol. 1992;82:729-734.